Anticancer drug targets: growth factors and growth factor signaling.
about
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivoEpidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cellsFrom oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.Targeted therapies for killing tumor cells.Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progressionReview of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma.ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.Chemotherapy for the treatment of metastatic brain tumors.Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors.Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin.Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin.EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell linesEGFR inhibitor enhances cisplatin sensitivity of human glioma cells.Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells.Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules.A sensitive dual-fluorescence reporter system enables positive selection of ras suppressors by suppression of ras-induced apoptosis.Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.Functional analysis of Csk and CHK kinases in breast cancer cells.Lysophosphatidic acid inhibits Ca2+ signaling in response to epidermal growth factor receptor stimulation in human astrocytoma cells by a mechanism involving phospholipase C(gamma) and a G(alphai) protein.Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling.Alterations in lens protein tyrosine phosphorylation and phosphatidylinositol 3-kinase signaling during selenite cataract formation.The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor.Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts.
P2860
Q24316195-254C2EA2-2964-4494-81C2-CE77F17CB881Q24792963-55490AA4-65B8-4866-89BF-BB6F6091D678Q30168082-3F2BB224-9C7A-4D79-8AD4-38759EEDDD82Q33942895-F3E5F73E-3A3D-46C6-A223-024C5436EF8FQ34360215-B63E820B-76F5-4DE0-A832-052BE6DB880CQ34394070-FFFD295A-92FE-4634-91F2-C60F3B42C052Q34481867-2D5DE6C0-2BB4-4E37-B862-FAF6EA4AFE38Q34519896-71B5BC4A-594B-49A0-A04F-5B6F61D07E18Q34969177-6D7778E4-79D7-4355-AE82-C6A7003085C2Q35541482-C9A2FC61-0EE4-4F6B-84ED-3B45AE90CED0Q35911472-8A8C2DFC-BF8C-4326-9040-E9C4417D7461Q36624124-3A3BB6E1-F894-466F-8225-BF9390D1B6C1Q37479804-1E249B61-CBAC-4FE8-9183-B429E845CD27Q37828640-EF7DF06D-3639-45BB-92FC-F2A1172159E7Q38611545-EB92E2A4-3E82-4C2A-A22F-1182162CC364Q38847029-8E3BC4BB-0C99-4F4B-B852-EF8A17BB113CQ39427603-1D9DB3D8-8A2A-452E-A5D8-4F3B80279962Q39533928-86A7B11A-2680-46DE-8D97-005A0E63D94BQ40430306-AA356F77-52E2-45FB-B176-B803C055B17EQ40535662-817F4845-B1A0-46E4-90AE-40E1F8F2AE9DQ40632774-2776DEED-B87D-45A5-909F-3FAC9CEE1032Q40757130-6FC4F169-7467-458D-8813-C40C933873C9Q40793615-5AD51E17-3516-4E63-91F0-683EA0A6AEDAQ40855100-FC9BDFF3-85B5-4218-90E7-15FE9F6066ACQ42063000-DB53CB0B-4539-490B-8D13-5F49A7D18EFEQ44769865-7F6138B4-E97B-4503-A1E7-B629129FB572Q45065769-27BB9C0A-61BE-45C6-9CF0-93D62342B64BQ46604197-78255713-5520-438F-9E70-F5A259935FECQ53919011-0932080A-359B-45C5-ADBF-BF1C3FB2E4B4
P2860
Anticancer drug targets: growth factors and growth factor signaling.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Anticancer drug targets: growth factors and growth factor signaling.
@ast
Anticancer drug targets: growth factors and growth factor signaling.
@en
type
label
Anticancer drug targets: growth factors and growth factor signaling.
@ast
Anticancer drug targets: growth factors and growth factor signaling.
@en
prefLabel
Anticancer drug targets: growth factors and growth factor signaling.
@ast
Anticancer drug targets: growth factors and growth factor signaling.
@en
P2860
P356
P1476
Anticancer drug targets: growth factors and growth factor signaling.
@en
P2093
P2860
P356
10.1172/JCI9084
P407
P577
2000-01-01T00:00:00Z